Dr. Reddys Labs (RDY) Reports Q3 EPS of $0.40
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
BofA/Merrill Lynch Downgrades Dr. Reddy's Laboratories (RDY) to Neutral
February 15, 2013 6:43 AM ESTBofA/Merrill Lynch downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Buy to Neutral following Q3 results.
For an analyst ratings summary and ratings history on Dr. Reddy's Laboratories click here. For more ratings... More
